Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Breast CancerStage I Breast CancerStage II Breast Cancer
Interventions
DRUG

Darbepoetin Alfa

Given day before chemotherapy of red blood cell count is below normal

DRUG

Pegfilgrastim

Given as an injection the day before chemotherapy for a total of 8 injections

DRUG

Paclitaxel

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

DRUG

Doxorubicin

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

DRUG

Cyclophosphamide

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

Trial Locations (6)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02130

Faulkner Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01854

Lowell General Hospital, Lowell

01960

North Shore Cancer Center, Peabody

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Lowell General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

North Shore Medical Center

OTHER

lead

Harold J. Burstein, MD, PhD

OTHER

NCT00146562 - Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | Biotech Hunter | Biotech Hunter